Pacira BioSciences (PCRX) Aktievy
Pacira BioSciences, Inc. bedriver utveckling, tillverkning, marknadsföring, distribution och försäljning av icke-opioida lösningar för smärtlindring och regenerativ hälsa till hälso- och sjukvårdspersonal i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 1/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
PCRX Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pacira BioSciences, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$23.21 |
| 52 veckors högsta | US$27.64 |
| 52 veckors lägsta | US$18.80 |
| Beta | 0.29 |
| 1 månads förändring | 0.26% |
| 3 månaders förändring | 1.66% |
| 1 års förändring | -6.67% |
| 3 års förändring | -37.20% |
| 5 års förändring | -61.11% |
| Förändring sedan börsintroduktionen | 230.63% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 03
PCRX: Real World Outcomes And Activist Pressure Will Drive Future Repricing
Analysts have kept Pacira BioSciences' fair value estimate steady at $38.00 while adjusting underlying assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects a mix of recent price target moves and updated views on the company’s data and outlook.Seeking Alpha • May 19
Pacira BioSciences: Exparel Still Supports My Original Bull Case
Summary PCRX remains a commercial non-opioid pain company built around Exparel, Zilretta, and Iovera. That’s why I think the most important catalysts for this stock, for better or worse, will be its upcoming 2026 pipeline readouts. But I reckon that PCRX’s overdependence on Exparel remains a factor worth considering, aside from other inherent biotech risks like patents and reimbursement policies, among others. Fortunately, PCRX’s recent pullback actually offers a discount on a relatively improved company compared to the first time I covered it. As such, I reiterate my “Buy” on PCRX. Read the full article on Seeking AlphaRecent updates
Uppdatering av berättelse • Jun 03
PCRX: Real World Outcomes And Activist Pressure Will Drive Future Repricing
Analysts have kept Pacira BioSciences' fair value estimate steady at $38.00 while adjusting underlying assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects a mix of recent price target moves and updated views on the company’s data and outlook.Seeking Alpha • May 19
Pacira BioSciences: Exparel Still Supports My Original Bull Case
Summary PCRX remains a commercial non-opioid pain company built around Exparel, Zilretta, and Iovera. That’s why I think the most important catalysts for this stock, for better or worse, will be its upcoming 2026 pipeline readouts. But I reckon that PCRX’s overdependence on Exparel remains a factor worth considering, aside from other inherent biotech risks like patents and reimbursement policies, among others. Fortunately, PCRX’s recent pullback actually offers a discount on a relatively improved company compared to the first time I covered it. As such, I reiterate my “Buy” on PCRX. Read the full article on Seeking AlphaUppdatering av berättelse • May 01
PCRX: Real World Procedure Data Will Support Future Upside Repricing
Analysts nudged their price target on Pacira BioSciences up by $2, citing slightly stronger modeled revenue growth of 17.50% and an 8.33% profit margin outlook, supported by recent real world data updates and mixed but active coverage on the stock. Analyst Commentary Recent research has been mixed, but the latest commentary highlights that bullish analysts are still finding reasons to lean constructive on Pacira BioSciences, especially around the updated revenue growth and margin framework that underpins the new price target.
Uppdatering av berättelse • Apr 16
PCRX: Real World Hip Data And Activist Pressure Will Shape Outlook
Analysts have reduced their Pacira BioSciences price target by $2, citing updated real world data in hip arthroplasty and revisions to growth, margin, and future P/E assumptions. Analyst Commentary Bearish analysts are flagging that updated real world hip arthroplasty data has introduced more uncertainty into Pacira BioSciences' outlook, leading to more cautious assumptions around growth, margin profile, and future P/E levels.Uppdatering av berättelse • Apr 01
PCRX: Higher 2026 Outlook And Activist Pressure Will Unlock Future Upside
Analysts have trimmed their Pacira BioSciences price target by $2, citing updated assumptions around faster revenue growth, a lower profit margin outlook, and a higher future P/E multiple. Analyst Commentary Despite the modest trim to the headline price target, bullish analysts see the updated assumptions as a way to reset expectations while keeping a constructive view on Pacira BioSciences.Uppdatering av berättelse • Mar 17
PCRX: Future Outlook Weighs Activist Board Push Against Asia Licensing Upside
Analysts have reaffirmed their $22.00 price target for Pacira BioSciences, noting small adjustments to revenue growth, profit margin assumptions, and a slightly lower future P/E multiple to reflect updated expectations for the company’s earnings profile. What's in the News DOMA Perpetual Capital Management nominated three director candidates for the 2026 annual meeting and called for the immediate replacement of CEO Frank Lee, the appointment of an interim CEO, and a formal sale process for the business (Investor activism, March 12, 2026).Uppdatering av berättelse • Mar 03
PCRX: Future Outlook Balances Asia Partnership Progress With Activist Pressure
Analysts have trimmed their price target on Pacira BioSciences from $24 to $22, reflecting updated assumptions that include a higher discount rate, more conservative revenue expectations, and lower projected profit margins, partly offset by a slightly higher future P/E multiple. What's in the News Issued full year 2026 earnings guidance, with total revenue expected in a range of $745 million to $770 million.Uppdatering av berättelse • Feb 17
PCRX: Asia Partnership Will Drive Future Upside Potential
Analysts have kept their $38.00 price target for Pacira BioSciences steady, with only small tweaks to assumptions around revenue growth, profit margins and future P/E that support this unchanged view. What's in the News Pacira BioSciences entered an agreement with LG Chem that gives LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.Uppdatering av berättelse • Feb 02
PCRX: Asia Partnerships And Pipeline Progress Will Drive Future Upside Potential
Analysts have reiterated a US$38.00 price target for Pacira BioSciences, citing slightly updated assumptions for revenue growth, profit margin, and future P/E that collectively leave their overall valuation view unchanged. What's in the News Pacira entered an agreement with LG Chem, giving LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets, with Pacira receiving an upfront payment, transfer price, and tiered royalties while LG Chem handles regulatory filings in South Korea and Thailand within six months (Client Announcements).Uppdatering av berättelse • Jan 19
PCRX: Asia Partnership And Pipeline Advances Will Drive Future Upside Potential
Narrative Update Analysts have kept their price target for Pacira BioSciences broadly steady around $38.00, citing slightly higher modeled revenue growth, a modestly lower profit margin outlook, and a similar forward P/E assumption. What’s in the News Pacira entered an agreement with LG Chem, granting LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.Analysartikel • Jan 17
Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive
Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shareholders won't be pleased to see that the share price has had a very rough...Uppdatering av berättelse • Jan 05
PCRX: Share Buybacks And Activist Pressure Will Support Future Upside Potential
Analysts have kept their fair value estimate for Pacira BioSciences steady at $38.00. The latest price target is grounded in updated assumptions for slightly different revenue growth, profit margin expectations, and a higher future P/E multiple.Uppdatering av berättelse • Dec 14
PCRX: Activist Pressure And Share Buybacks Will Unlock Future Upside Potential
Analysts have modestly raised their price target on Pacira BioSciences to $38.00 from $36.00, citing expectations for slightly stronger long term profitability despite a somewhat more conservative revenue growth outlook and valuation multiple. What's in the News Activist investor DOMA Perpetual Capital Management sent a letter to Pacira's board urging the company to hire bankers and pursue a full sale process, citing persistent underperformance and overspending (Key Developments).Analysartikel • Nov 13
Pacira BioSciences' (NASDAQ:PCRX) Strong Earnings Are Of Good Quality
When companies post strong earnings, the stock generally performs well, just like Pacira BioSciences, Inc.'s...
Uppdatering av berättelse • Aug 17
Policy Changes And Partnerships Will Expand Ambulatory Market Reach
The slight decrease in consensus revenue growth expectations and a lower future P/E multiple have led analysts to reduce their fair value estimate for Pacira BioSciences from $30.60 to $29.00. What's in the News Pacira completed a $50.04 million buyback, repurchasing 1,955,589 shares (4.23%) under its May 2025 authorization and previously completed a $25 million buyback (837,240 shares, 1.8%) under its May 2024 authorization.Analysartikel • Jun 11
Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Apr 09
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act
Summary PCRX focuses on non-opioid pain management with Exparel, Zilretta, and iovera, delivering targeted pain relief with fewer side effects. A key secular tailwind for them comes from the NOPAIN Act, which creates separate reimbursement and grows access to non-opioid therapies. Also, PCRX’s PCRX-201 is a promising new gene therapy for knee osteoarthritis, which so far has shown promising results and targets a sizeable TAM. I also like how PCRX reached important patent settlements that secure its competitive prospects with Exparel’s exclusivity until 2030. In my view, PCRX remains undervalued at these levels, which is why I consider it a “Buy” despite its inherent biotech risks. Read the full article on Seeking AlphaAnalysartikel • Apr 07
Pacira BioSciences, Inc. (NASDAQ:PCRX) Looks Inexpensive But Perhaps Not Attractive Enough
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) is a stock...Seeking Alpha • Mar 14
Pacira BioSciences: Back On An Uptrend After Positive Developments
Summary Pacira BioSciences, Inc.'s stock is up 33% since my last “Buy” rating, driven by strategic moves and market overreaction correction. The company has secured a new patent for its lead pain therapeutic, Exparel, delaying generic market entrants, and potentially protecting its market share until mid-next decade. Vertex's Journavx launch may boost awareness for non-opioid pain relief, benefiting Pacira's Exparel under the NOPAIN Act. Pacira's new five-point plan aims for growth, profitability, and pipeline expansion, positioning it for potential blockbuster revenue and market leadership. The positive steps PCRX has taken since my last note means there is no change to my “buy” thesis. Read the full article on Seeking AlphaAnalysartikel • Jan 30
Pacira BioSciences (NASDAQ:PCRX) Has A Rock Solid Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Jan 03
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
You may think that with a price-to-sales (or "P/S") ratio of 1.2x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) is a stock...Seeking Alpha • Nov 25
Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
Summary Pacira BioSciences markets and sells EXPAREL, a non-opioid pain relief therapy. The drug drives revenues of >$500m per annum, but a new generic version has been approved, while Pharma giant Vertex is close to having a similar drug approved. Pacira's share price has plummeted from >$80 in mid-2022 to ~$18 today, as the market sees little growth in the business and notes the competitive threats. The market may be a little too pessimistic - Vertex's drug is unproven in the market while generics may be held off for many more years. EXPAREL's peak years may still be ahead - PCRX stock could recoup some deserved value if it can share positive Q4 earnings, update on legal matters, and keep developing its pipeline. Read the full article on Seeking Alpha
Ny berättelse • Sep 24
EXPAREL's Calculated Expansion And Innovative R&D Bolster Market Dominance Amidst Challenges
Expanding EXPAREL utilization in outpatient settings and through GPO partnerships aims to enhance revenue by increasing market penetration and affordability.Analysartikel • Sep 06
Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%
To the annoyance of some shareholders, Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shares are down a considerable 34% in...Aktieägarnas avkastning
| PCRX | US Pharmaceuticals | US Marknad | |
|---|---|---|---|
| 7D | 4.3% | 5.6% | -3.3% |
| 1Y | -6.7% | 37.6% | 22.3% |
Avkastning vs industri: PCRX presterade sämre än US Pharmaceuticals branschen som gav 37.6 % under det senaste året.
Avkastning vs Marknaden: PCRX presterade sämre än US marknaden som gav 22.3 % under det senaste året.
Prisvolatilitet
| PCRX volatility | |
|---|---|
| PCRX Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: PCRX har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: PCRX s veckovolatilitet ( 5% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2006 | 827 | Frank Lee | www.pacira.com |
Pacira BioSciences, Inc. är verksamt inom utveckling, tillverkning, marknadsföring, distribution och försäljning av icke-opioida lösningar för smärtlindring och regenerativ hälsa till hälso- och sjukvårdspersonal i USA. Företaget erbjuder EXPAREL, en injicerbar suspension av bupivakainliposomer för postoperativ smärtlindring, ZILRETTA, en injicerbar suspension av triamcinolonacetonid med förlängd frisättning för behandling av artros och knäsmärta, och iovera system, en icke-opioid handhållen kryoanalgesiapparat som används för att leverera kontrollerade doser av kall temperatur till utvalda nerver för att producera neurolytisk blockering som avbryter de smärtöverförande signalerna i en perifer nerv. Företaget utvecklar också PCRX-201, en ny vektorplattform för genterapi som möjliggör lokal administrering av genetiska läkemedel med potential att behandla stora folksjukdomar som artros.
Pacira BioSciences, Inc. Sammanfattning av grunderna
| PCRX grundläggande statistik | |
|---|---|
| Börsvärde | US$899.49m |
| Vinst(TTM) | US$5.14m |
| Intäkter(TTM) | US$734.86m |
177.7x
P/E-förhållande1.2x
P/S-förhållandeÄr PCRX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| PCRX resultaträkning (TTM) | |
|---|---|
| Intäkter | US$734.86m |
| Kostnad för intäkter | US$151.86m |
| Bruttovinst | US$583.01m |
| Övriga kostnader | US$577.87m |
| Intäkter | US$5.14m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 0.13 |
| Bruttomarginal | 79.34% |
| Nettovinstmarginal | 0.70% |
| Skuld/egenkapitalförhållande | 56.2% |
Hur har PCRX utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/09 04:32 |
| Aktiekurs vid dagens slut | 2026/06/09 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Pacira BioSciences, Inc. bevakas av 29 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jenna Davidner | Barclays |
| Anita Dushyanth | Berenberg |
| Gary Nachman | BMO Capital Markets Equity Research |